Home / Health / New Obesity Drugs Launched in India for 2025
New Obesity Drugs Launched in India for 2025
24 Jan
Summary
- Obesity is a global health crisis, affecting over a billion people worldwide.
- GLP-1 RA drugs, like Ozempic, Wegovy, and Mounjaro, launched in India in 2025.
- Nearly one in four Indians are now obese, with rural and lower-income groups affected.
Obesity has become a critical global public health issue, with over a billion people affected worldwide and rising prevalence in nearly every nation, including India. Recent data indicates that almost one in four Indian adults is now obese, a trend observed in both urban and rural areas, and across socioeconomic strata.
The year 2025 marked a significant development with the introduction of GLP-1 Receptor Agonist (GLP-1 RA) drugs in India. These medications, including Ozempic, Wegovy, and Mounjaro, mimic the body's GLP-1 hormone to help manage Type 2 diabetes and chronic obesity. They work by regulating blood sugar, slowing digestion, and reducing appetite, contributing to sustained weight loss.
A survey revealed that while 6 in 10 Indians are already dealing with obesity-related complications, a substantial portion still views obesity as a lifestyle choice rather than a medical condition. Awareness of prescription treatments like GLP-1 RAs remains low, with only 16% of respondents well-informed.
Managing obesity offers numerous health benefits, including improved metabolic health, stabilized blood sugar, and reduced risk of Type 2 diabetes. Furthermore, weight loss positively impacts cardiovascular health, lowering blood pressure and cholesterol levels, while also potentially reversing conditions like fatty liver disease and improving joint health.
